Layoffs
Earlier this month, Novo Nordisk announced it was laying off 400 staffers in Denmark and China. Today, Reuters reports that the Danish company plans to lay off about 250 people in the United States.
Swiss pharmaceutical giant Novartis plans to slash approximately 2,200 jobs in Switzerland over the next four years.
Novo Nordisk is laying off 400 staffers so it can shift funds toward biological and technological innovation.
Following a trial failure with its atopic dermatitis treatment, Malvern, Penn.-based Realm Therapeutics has opted to discontinue all of its drug development programs and is considering a potential sale of the company.
Takeda Pharmaceuticals will shutter its Deerfield, Ill. U.S. headquarters and move the operations to Boston as the company consolidates its operations following the $62 billion acquisition of Shire.
Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.
A patient advocacy organization is putting its weight behind an effort to urge the U.S. Food and Drug Administration to reconsider its recent decision to reject a treatment for the rare lipid disorder familial chylomicronemia syndrome (FCS). That rejection lead to a round of layoffs at Akcea.
As part of an earlier announced restructuring program, UK-based GlaxoSmithKline is laying off 650 staffers in the U.S. GlaxoSmithKline employees approximately 15,000 people in the U.S.
Genentech is slashing 223 jobs at its South San Francisco headquarters, according to a Worker Adjustment and Retraining Notification posted on a California state government website. The layoffs will go into effect on Aug. 31, according to the WARN posting.
Two days after Boston Scientific laid off 85 employees at a Burlington, Mass. manufacturing site, the company forked over up to $160 million to acquire California stent maker Veniti, Inc. The deal marks the third acquisition for Boston Scientific in two months.
PRESS RELEASES
